Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivasorexant DDI with flurbiprofen, omeprazole, and midazolam
NCT05254548Phase 1Completed
- Sponsor
- Idorsia
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivasorexant in binge eating disorder (BED), sponsored by Idorsia. Primary endpoints: Maximum plasma concentration (Cmax) of each probe substrate: flurbiprofen, midazolam and omeprazole, Time to reach Cmax (tmax) of each probe substrate: flurbiprofen, midazolam and omeprazole and 3 more. Started Feb 2022; status: completed.
02
Drugs
nivasorexant
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT05254548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254548.